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ABSTRACT 12 
Some intervention studies have shown that quercetin supplementation can regulate certain biomarkers, 13 
but it is not clear how the doses given relate to dietary quercetin (e.g. from onion). We conducted a 14 
two-period, two-sequence crossover study to compare the bioavailability of quercetin when 15 
administered in the form of fresh red onion meal (naturally glycosylated quercetin) or dietary 16 
supplement (aglycone quercetin) under fasting conditions.  Six healthy, non-smoking, adult males with 17 
BMI 22.7 ± 4.0 kg m-² and age 35.3 ± 12.3 y were grouped to take the two study meals in random 18 
order. In each of the 2 study periods, one serving of onion soup (made from 100 g fresh red onion, 19 
providing 156.3 ± 3.4 µmol (47 mg) quercetin) or a single dose of a quercetin dihydrate tablet (1800 ± 20 
150 µmol (544 mg) of quercetin) were administered following 3 d washout. Urine samples were 21 
collected up to 24 h, and after enzyme deconjugation, quercetin was quantified by LC-MS. The 24-h 22 
urinary excretion of quercetin (1.69 ± 0.79 µmol) from red onion in soup was not significantly different 23 
to that (1.17 ± 0.44 µmol) for the quercetin supplement tablet (P = 0.065, paired t-test). This means 24 
that, in practice, 166 mg of quercetin supplement would be comparable to about 10 mg of quercetin 25 
aglycone equivalents from onion. These data allow intervention studies on quercetin giving either food 26 
or supplements to be more effectively compared.   27 
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INTRODUCTION 28 
Quercetin is a flavonoid (class: flavonol) that is present at high levels in onions, apples and tea, in the 29 
form of a 3-O-glucoside, 4'-O-glucoside or 3,4'-O-diglucoside. Intervention studies using those foods to 30 
examine long term effects are rare, not only because of the extensive food preparation required with 31 
consistent composition, but also that volunteers grow tired of the same food for months which limits 32 
compliance.  33 
Many studies using quercetin supplements (aglycone) in humans indicate effects on antioxidant status, 34 
oxidized LDL, inflammation and metabolism (summarised in Table 1, supplementary information). 500 35 
mg quercetin supplementation twice per day improved the NIH (National Institution of Health) 36 
prostatitis symptom score after 30 d in 30 men with chronic pelvic pain syndrome 1 and improved 37 
cystitis symptoms after 28 d in 22 interstitial cystitis patients 2. 150 mg of quercetin significantly 38 
affected expression of key genes, glycolipid catabolism, cell proliferation and apoptosis after 42 d 39 
intake in 20 subjects with a cardiovascular risk phenotype 3, and decreased systolic blood pressure, 40 
serum HDL-cholesterol, and plasma concentrations of atherogenic oxidised LDL in 96 healthy subjects 41 
4
. Daily consumption of 100 mg quercetin for 70 d reduced serum total and LDL/HDL cholesterol, 42 
glucose and systolic and diastolic blood pressure in 49 health subjects 5. 14 d of daily dose of 30 mg 43 
quercetin improved the oxidative resistance of LDL 6 and significantly decreased tissue inhibitor of 44 
metallopeptidase-1 (TIMP-1) in plasma and lymphocyte mRNA 7 in healthy subjects.  45 
Whether dietary quercetin could achieve the same effects remains unknown since the bioavailability of 46 
quercetin aglycone in supplements is much lower than quercetin glucoside 8 and this makes 47 
interpretation and comparison of studies using supplements or foods difficult. This randomized, single-48 
blind, two period, two sequence, cross-over intervention study, conducted under fasting conditions with 49 
a 3 d washout period, compared different dosages of quercetin from dietary supplements (aglycone) 50 
and fresh red onion (naturally conjugated as glucosides). This comparison allows calculation of the 51 
dosage of different quercetin sources needed to achieve similar effective absorption in healthy subjects 52 
to aid in the design of meaningful intervention studies.   53 
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SUBJECTS AND METHODS  54 
Chemicals and enzymes 55 
Absolute methanol, ethanol, acetonitrile (LC-MS grade) and ethyl acetate were from VWR 56 
international, France; ascorbic acid was from MP Biomedicals, LLC, France; formic acid, sodium 57 
acetate trihydrate, acetic acid, hydrochloric acid, ȕ-glucuronidase from Helix pomatia, and sulfatase 58 
from Helix pomatia, were purchased from Sigma-Aldrich, USA. Standards of quercetin dihydrate, 59 
quercetin 4'-O-glucoside (spiraeoside), quercetin 3,4'-O-diglucoside, isorhamnetin (3-O-60 
methylquercetin), tamarixetin (4'-O-methyquercetin ), daidzein and taxifolin, are all HPLC grade and 61 
were purchased from Extrasynthese, France.  62 
Subjects 63 
Six healthy male volunteers participated in the present study. They were non-smokers, not on any 64 
medication, aged 35.3 ± 12.3 y (range 20.0 - 48.9) and had a BMI of 22.7 ± 4.0 kg m-2 (range 18.5 - 65 
29.9). Exclusion criteria were metabolic and endocrine diseases, malabsorption syndromes, alcohol 66 
abuse, use of dietary supplements or any form of regular medication. All subjects were asked to 67 
maintain their normal lifestyle and usual extent of physical activities throughout the study. This study 68 
was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures 69 
involving human subjects were approved by the MaPS and Engineering joint Faculty Research Ethics 70 
Committee (MEEC 12-019), University of Leeds, UK. Written informed consent was obtained from all 71 
subjects.  72 
Study design 73 
The study was conducted with a single-blinded (researcher blind), diet-controlled, cross-over design. 74 
Subjects were required to avoid flavonols in the diet for 3 d washout prior to the breakfast and for 1 d 75 
during 24-h urine collection. For this purpose, a list of food items rich in flavonols was given to each 76 
participant as a guideline. This diet excluded vegetables like onion, spring onion, shallots, leeks, 77 
chives, spinach, kale, endive, lettuce, broccoli, asparagus, tomato, olive, pepper, courgette, green beans, 78 
broad bean, common bean and galangal; all types of berries and currants, apple, apricot, grape and 79 
plum; all types of alcoholic beverages and tea; and propolis supplements. On the morning of the study, 80 
baseline urine was collected immediately before breakfast and 24-h urine was collected following the 81 
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breakfast. The six participants were randomly assigned to treatment group A or B (n = 5 and 1). Group 82 
A ingested one quercetin supplement (1800 ± 150 µmol quercetin equivalents) with a standard 83 
breakfast; after another 3 d washout, they ingested onion-enriched soup (156.3 ± 3.4 µmol quercetin 84 
equivalents). Group B had treatments in reverse order to Group A. The baseline urine was used as 85 
compliance control and no apparent deviation from the low-quercetin diet was observed. Accordingly, 86 
the concentrations of quercetin were very low (0.095 ± 0.037 µM, SEM) in baseline urine. 87 
Preparation of standard breakfasts 88 
Red Onion Soup Fresh local red onions were washed, skinned and sliced after removing the top and 89 
bottom of the bulb. The slices were frozen at-ࡈC for 1 h and quickly minced with a kitchen 90 
electronic blender while still frozen. 100 g of the onion mince was stored individually at-ࡈC until the 91 
day of the human study. A breakfast was freshly made consisting of one portion of instant tomato soup 92 
mix 52 g (Slim a Soup, Batchelorsrange, UK) and 100 g of frozen onion by adding hot water and 93 
stirring into a soup-paste after heating in a 800 W microwave for 1 min. The standard meal was served 94 
with buttered white bread. The soup powder did not contain any quercetin. 95 
Supplement Quercetin dihydrate tablets (500 mg stated, actual measured 544 mg (see Results)) were 96 
Purchased from Nature's Best (Kent, UK) without further processing. One tablet was consumed with 97 
buttered white bread and instant tomato soup as above. 98 
HPLC Quantification of quercetin in study food 99 
The quercetin content of the red onion soup and of the supplement tablet was determined by HPLC-100 
diode-array analysis. To 5 g of frozen red onion, 5 ml of absolute methanol was added and to 0.4 g 101 
soup powder, 5 ml of 70% methanol was added. Extraction was performed using ultra sonication and 102 
vortex. The samples were centrifuged (3000 gࡈC, 10 min) and the supernatant was collected. The 103 
extraction was repeated twice with 5 ml of 70% aqueous methanol (containing 0.1 mM ascorbic acid, 104 
pH 5.08). 1 ml of the combined extracts was fully dried in a centrifugal evaporator (Genevac Ltd, 105 
Ipswich, UK), and then reconstituted with 1 ml of 50% aqueous ethanol containing 100 µM daidzein as 106 
internal standard. Before HPLC analysis, the samples were filtered through polytetrafluoroethylene 107 
(PTFE) membrane syringe filter (pore size of 0.2 µm). Extraction was performed in duplicate for each 108 
food sample. 109 
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The reconstituted samples were analyzed on an Agilent HPLC 1200 instrument (Agilent Technologies, 110 
Waldbronn, Germany) equipped with C18 column (ZORBAX Eclipse XDB-C18, 4.6×50 mm, 1.8 µm 111 
particle size, rapid resolution high throughput, 600 bar column, Agilent, USA) and a pre-column 112 
(Eclipse XDB-C18, 4.6×12.5 mm, 5 µm, analytical guard cartridge, Agilent, USA). 113 
A modified version of the analytical HPLC method from 9 and 10, was used. Solvents A (water with 114 
0.1% v/v of formic acid) and B (acetonitrile with 0.1% v/v of formic acid) were run at a flow rate of 0.5 115 
ml min-1. The chromatographic conditions of elution were as follows: 0 - 2 min, 15% solvent B; 2 - 22 116 
min, increase solvent B from 15% to 40%; 22 - 24 min, isocratic for 2 min. A post-run column clean up 117 
procedure was applied by increasing B to 90% in 1 min, isocratic for 3 min and finally rapidly 118 
returning to initial conditions with re-equilibration at 29 min for 5 min of 15% B. Each sample (10 µl) 119 
was injected and analyzed twice. A column clean-up stage maintained B at 90% (30 min) which was 120 
followed by a re-equilibration at 15% B (30 min) to initiate each new batch of analysis. Diode array 121 
detection monitored the eluent at 255 nm and 370 nm. A standard curve ranging from 15.6 to 1000 122 
pmol quercetin equivalents was produced using standard solutions of quercetin 3,4'-O-diglucosides 123 
(AUC370nm of 0.736/pmol), quercetin 4'-O-glucoside (AUC370nm of 1.49/pmol), daidzein (AUC255nm of 124 
1.68 ± 0.01/pmol), and quercetin (AUC370nm of 1.26/pmol), with retention times of 3.20, 9.44, 12.6 and 125 
14.3 min, respectively. HPLC chromatograms of standard mix, supplement extract and red onion 126 
extract are shown in Figure 1. 127 
After HPLC analysis to confirm that the supplement contained pure quercetin (Figure 1), the 128 
quantification was performed by spectrophotometry using the extinction coefficient (İ) at 129 
Ȝmax(quercetin)/nm 257 (İ/mM-1 cm-1, 19.95) and 376 (21.88) against 95% aqueous ethanol 11. In brief, 130 
5 tablets were finely ground in an electric coffee grinder and about 2 mg of the powder was accurately 131 
weighed and fully dissolved in 95% ethanol. Absorbance spectra were compared with quercetin 132 
standards prepared in 95% ethanol. 133 
Processing of urine samples and analysis of quercetin in urine 134 
24-h urine was collected into a 3 L sterile urine storage container with 3 g of ascorbic acid added. Once 135 
the sample arrived at the laboratory, the weight was measured and two 45 ml aliquots were taken into 136 
50 ml falcon tubes, then centrifugedDWJDWࡈC for 10 min7KHVXSHUQDWDQWZDVVWRUHGDW-ࡈC 137 
until analysis. 138 
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Enzyme hydrolysis of quercetin conjugates and liquid phase extraction  139 
Metabolites of methyl-, glucuronyl-, glucosyl- and sulfo-conjugates of quercetin in human urine were 140 
hydrolysed to quercetin and the monomethylated derivatives isorhamnetin (3-O-methylquercetin) and 141 
tamarixetin (4'-O-methylquercetin) XVLQJȕ-glucuronidase and sulfatase 12. To 200 µl of urine, 20 µl of 142 
0.2 M sodium acetate - acetic acid buffer, pH 5.0 containing XQLWVȕ-glucuronidase and 5 units of 143 
sulfatase were added; 2 µl of 100 µM taxifolin was added as internal standard, then incubated in a 144 
VKDNLQJZDWHUEDWKDWࡈC, 100 rpm for 1 h. The completion of hydrolysis of all quercetin conjugates 145 
was assured by parallel experiments running from 1 h every 0.5 h up to 3 h. Results showed that 146 
hydrolysis was complete within 1 h as evidenced by the concentration of quercetin aglycone and 147 
isorhamnetin reaching a plateau. The pH of the hydrolysis mixture was adjusted to 2.0 by addition of 148 
30 µl of 0.1 M HCl. To the hydrolysis mixture (about 250 µl), 500 µl of ice-cold ethyl acetate was 149 
added, mixed vigorously by vortex for 2 min, followed by standing on ice for 2 min and centrifugation 150 
at room temperature at 17,000 g for 2 min. The procedure was repeated twice and 3 supernatants 151 
pooled. Extracts were fully dried by nitrogen gas, then reconstituted with 150 µl of 50% ethanol and 152 
filtered through 0.2 µm PTFE filters before analysis. An enzyme unit was GHILQHGDWࡈC at pH 5.0 153 
DFFRUGLQJWRWKHPDQXIDFWXUHURQHXQLWRIȕ-JOXFXURQLGDVHOLEHUDWHVȝJRISKHQROSKWKDOHLQIURP154 
SKHQROSKWKDOHLQJOXFXURQLGHSHUKRQHXQLWRIVXOIDWDVHK\GURO\]HVȝPRO4-nitrocatechol sulfate 155 
per h. Extraction was performed in duplicate for each biological sample. 156 
HPLC-ESI/MS 157 
Analysis of urine concentrations of quercetin and of the monomethylated derivatives: isorhamnetin (3-158 
O-methylquercetin) and tamarixetin (4'-O-methylquercetin) was performed by HPLC with mass 159 
spectrometry using a Shimadzu LC-2010C HT with single ion monitoring (Shimadzu, Tokyo, Japan) 160 
operated in negative electrospray ionization (-ESI) mode. Nitrogen was used both as drying and 161 
nebulizing gas at a flow rate of 15.0 L h-1 and 1.5 L h-1. The DL temperature was maintained at 2ࡈC 162 
with detector voltage set at 1.80 kV and interface voltage at -3.5 kV. The standard curve was 0.05 - 163 
2.00 µmol, within-run variance was 6.8 ± 5.6% and between-run variance was 14.5 ± 8.2%. The 164 
recovery of quercetin extraction from urine was calculated using the yield of taxifolin (internal 165 
standard, 111 ± 14.3%, n = 92). All chromatograms in the same batch were processed automatically by 166 
software (Labsolutions, ver. 5, Shimadzu, Tokyo, Japan) using the same processing parameters, such as 167 
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integration, peak-to-peak amplitude, and peak detection. Manual integration was performed only rarely 168 
when necessary. 169 
Figure 2 shows a typical LC-MS Chromatogram of quercetin and conjugates after enzymatic hydrolysis 170 
of urine. The retention times of quercetin (m/z 301), isorhamnetin (m/z 315), tamarixetin (m/z 315) and 171 
taxifolin (m/z 303) are 16.1 min, 20.4 min, 20.6 min and 8.8 min, respectively. 172 
Statistical analysis 173 
All statistical analyses were performed using the SPSS statistics software (version 21; International 174 
Business Machines Corp., New York, USA). Normality of data distribution was checked with the 175 
Shapiro-Wilk test and data are normally distributed; independent samples t test was used to compare 176 
means between treatments. All calculations were carried out with CI 95%, and differences were 177 
considered significant at P < 0.05. Unless otherwise indicated, the results were reported as mean values 178 
with their standard deviations. 179 
RESULTS 180 
Control variables and intervention compliance 181 
The baseline urine was used as compliance control and no deviation from the low-quercetin diet was 182 
observed. Accordingly, the concentration of quercetin was very low 0.095 ± 0.037 µM (SEM) in 183 
baseline urine. 184 
Quercetin content of the study meals 185 
Based on individual analysis of compounds, red onion soup contained 156.3 ± 3.4 µmol quercetin 186 
equivalents per portion made from 100 g fresh red onion (quercetin 3, 4'-O-diglucoside 59.3% and 187 
quercetin 4'-O-glucoside 40.7%, molar equivalents). Quercetin dihydrate tablets contained 1800 ± 150 188 
µmol of quercetin (100% quercetin aglycone).  189 
Urinary excretion of quercetin 190 
The 24-h urinary excretion of quercetin for each individual after consuming a meal of 100 g red onion 191 
or a single study tablet is shown in Figure 3.  192 
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24-h urinary excretion of quercetin after consuming red onion soup, made from 100 g fresh red onion, 193 
was 1.69 ± 0.79 µmol (of which 72.9 ± 6.0% of quercetin, 7.70 ± 5.92% of isorhamnetin and 19.4 ± 194 
5.95% of tamarixetin), and that from the 500 mg quercetin supplement was 1.17 ± 0.44 µmol (71.4 ± 195 
11.1%, 7.54 ± 6.38% and 21.0 ± 11.7%). No significant difference in quercetin excretion was observed 196 
within subject (P = 0.065, paired t test) or among groups (P = 0.189, independent t test, n = 6) for the 197 
total quercetin.  198 
DISCUSSION 199 
The aim of the present randomized, single-blind, two-period, two-sequence, cross-over intervention 200 
study, conducted under fasting conditions with a 3 d washout period, was to compare the absorption of 201 
quercetin from fresh red onion (156.3 ± 3.4 µmol, naturally conjugated) and dietary supplements (1800 202 
± 150 µmol, aglycone) in healthy subjects. This resulted in similar amounts of quercetin being 203 
absorbed as assessed by quantifying 24-h urinary excretion of quercetin.  204 
Quercetin supplementation dose-dependently increases plasma quercetin concentrations in healthy 205 
humans 13, and incorporation of the washout period was designed to diminish the impact of carryover 206 
effects. According to other reports, the plasma concentrations after quercetin-4'-O-glucoside 207 
supplementation (equivalent to 100 mg quercetin) reached a peak after 0.7 ± 0.3 h and the apparent 208 
elimination half-life was about 11 h 14. Quercetin accumulated in plasma after repeated intake of onion 209 
(elimination half-life of 28 h), apples (elimination half-life of 23 h) and tea 8, but a steady state 210 
concentration in plasma was reached after about 4 d 15 and so plasma concentrations would reflect the 211 
intake of only the previous 3 d. For this reason, the length of the washout period was designed to be 3 212 
d.  213 
24-h urinary excretion of quercetin after consumption of red onion (mainly glucoside conjugated 214 
quercetin) and supplement (quercetin aglycone) was significantly different when compared by 215 
percentage dose (P < 0.0001, paired t test, 1.08 ± 0.51% and 0.065 ± 0.024%). These values are 216 
consistent with other human studies. For example, 24-h urinary excretion of quercetin as a proportion 217 
of intake after consumption of conjugated quercetin from fried onion was 0.8 ± 0.4% 16 and 1.1 ± 0.5% 218 
17
. 13-h urinary excretion of quercetin as a proportion of intake from onion was 0.31 ± 0.14% and that 219 
from 100 mg quercetin aglycone was 0.12 ± 0.08% 18. A systematic review confirmed that the 220 
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correlation between the dose of quercetin ingested and its recovery in 24-h urine samples in humans is 221 
on average 0.43% but with recovery ranging from 0.07 to 8.4% with this range at least partially due to 222 
the nature of the sugar conjugated to quercetin 19. It should be noted that the amount in urine reflects 223 
the minimum amount of quercetin absorbed, and other experiments such as intestinal perfusion show 224 
that the actual amount absorbed is considerably higher 20. Nevertheless, the amount in urine is a 225 
suitable biomarker for some polyphenols since it allows comparisons between different foods or 226 
supplements, and between individuals for the same compound 8, 21. The low amount of compounds such 227 
as quercetin in the urine means that the remainder of the dose is either excreted in the bile, in the faeces 228 
or may end up as chemically-altered microbial metabolites, which can then be absorbed in the colon 22. 229 
Typical microbial metabolites of quercetin are 3,4-dihydroxyphenylacetic acid, 3,4-dihydroxybenzoic 230 
acid and 3-hydroxyphenylacetic acid 23. After absorption, these compounds participate in metabolism 231 
and so may ultimately contribute to the physiological effects of quercetin 24. Even though the amount 232 
of intact quercetin in urine after these dosages of supplementation and onion intake were similar, it is 233 
likely that the supplement will deliver higher concentrations of microbial metabolites to the blood. 234 
Supplements have consistent quality and a relatively long shelf life, and are preferred in many 235 
intervention studies since they remove the complication of the activity of other components in the food, 236 
and are well tolerated long-term by volunteers. However, it is important to know the ³equivalence´ of 237 
quercetin-containing foods and supplements, to allow for future design and to compare existing studies. 238 
According to the result of this study in practical terms, 100 g of onion gives a comparable amount of 239 
quercetin in the urine to a 500 mg quercetin aglycone supplement. Based on this data, we can compare 240 
reported intervention studies on quercetin from onions and from supplements (Table 2, supplementary 241 
information), which lists the human intervention studies using dietary sources of quercetin. The 242 
obvious difference between the dose ranges between Table 1 and Table 2 (supplementary information) 243 
may explain, for example, why plasma LDL/HDL reduction after 14 d administration was observed by 244 
Kim et al. 25 but not by Egert et al. 13 or Chopra et al. 6. This pilot study provides a guideline for design 245 
of future human studies when using supplements and foods, and also facilitates comparison of studies 246 
in existing literature.  247 
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Supplementary information: Table 1 Human intervention studies on quercetin supplementation1 314 
Dose per day2 Days 
No. of 
subjects per 
group3 
Biomarkers significantly affected Biomarkers not significantly affected Ref 
500 mg x 2 30 30 men with 
chronic 
pelvic pain 
syndrome 
Improvement in NIH prostatitis symptom 
score 
 
1
 
500 mg x 2 28 22 
interstitial 
cystitis 
patients 
Improvement in cystitis symptoms No side effects or adverse reactions 2 
250 mg x 4 21 63  Blood antioxidant capacity or plasma lipid 
during ultramarathon 
26
 
150 mg 14 12  6HUXPXULFDFLGSODVPDĮ- DQGȖ-
tocopherols, oxidized LDL, tumour 
necrosis factor-Įserum lipids and 
lipoproteins, plasma antioxidant capacity, 
body composition, or  resting energy 
expenditure supplementation 
13
 
150 mg 42 20 with 
cardiovascul
ar risk 
phenotype 
Gene expression of  C1GALT1, O-glycan 
biosynthesis; GM2A, glycolipid 
catabolism; HDGF, cell proliferation; 
SERPINB9, apoptosis 
Gene expression of the other target genes 3 
150 mg 42 96 Decrease of systolic blood pressure, serum 
HDL, plasma concentrations of atherogenic 
oxidised LDL 
Total cholesterol, TAG,  LDL/HDL, 
TAG/HDL, TNF-Į, C-reactive protein, 
nutritional status, blood parameters of liver 
and kidney function, haematology or serum 
electrolytes 
4
 
100 mg 70 49 Increase of HDL; decrease of serum total 
cholesterol and LDL; decrease of systolic 
and diastolic blood pressure, blood glucose 
Inflammatory IL-6, sVCAM-1 5 
30 mg 14 10 Improved oxidative resistance of LDL Plasma triglycerides, HDL or LDL 6 
30 mg 14 4 Decrease in TIMP-1 plasma protein and 
lymphocyte mRNA 
TIMP-2 and matrix metalloprotein-2 
lymphocyte mRNA or plasma protein 
7
 
500 mg 
quercetin-3-O-
glucoside 
7 15  Repeated-sprint performance, percent 
fatigue decrement, blood xanthine oxidase 
activity, IL-6 or uric acid 
27
 
1
 Some of the entries were derived from 28 315 
2
 Quercetin aglycone, unless otherwise stated. 316 
3
 Healthy subjects, unless otherwise stated. 317 
Abbreviation: NIH, national institution of health; C1GALT1, Core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-318 
galactosyltransferase; GM2A, ganglioside monosialic 2 activator; HDGF, hepatoma-derived growth factor; SERPINB9, 319 
Serpin B9; IL-6, Interleukin 6; sVCAM-1, soluble vascular cell adhesion molecule 1; TIMP-1, tissue inhibitor of 320 
metallopeptidase -1; TIMP-2, tissue inhibitor of metallopeptidase-2. 321 
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Supplementary information: Table 2 Human intervention studies on dietary quercetin1 323 
Dose per day2 Quercetin 
equivalent3 
Day
s 
No. of subjects 
per group4 
Biomarkers significantly 
affected 
Biomarkers not significantly 
affected Ref 
76-110 mg 
quercetin and 
other 
flavonols from 
400 g onion 
(with tomato 
sauce) + 6 
cups of tea 
1200-1800 
mg with other 
14 10 type 2 diabetic 
patients 
Decrease oxidative damage 
to lymphocyte DNA 
Fasting plasma glucose, 
fructosamine, vitamin C, 
carotenoids, Į-tocopherol, 
urate, albumin and bilirubin 
29
 
200 g onion 1500 mg 1 6 female Increase resistance of 
lymphocyte DNA to strand 
breakage, decrease in 
urinary 8-hydroxy-2'-
deoxyguanosine 
Urinary malondialdehyde 30 
21 mg dietary 
quercetin, 9 
mg dietary 
kaempferol 
350 mg with 
other 
1 19 female Increase in erythrocyte 
superoxide dismutase 
activity, decrease in 
lymphocyte DNA damage 
(tail moment) 
3ODVPDĮ-tocopherol or ȕ-
carotene 
31
 
51 mg 
quercetin from 
4.3 g onion 
extract 
850 mg 30 23 male with oral 
maltose load 
induced 
postprandial 
endothelial 
dysfunction 
Increase postprandial flow-
mediated vasodilation 
(FMD) responses 
Fasting FMD systemic or 
forearm hemodynamic 
32
 
100 mg 
quercetin + 
128 mg other 
flavonoids, 
onion peel 
extract 
1660 mg with 
other 
14 12 female Decrease total cholesterol 
level, LDL cholesterol and 
atherogenic index 
Erythrocyte antioxidant 
enzymes, lipid peroxidation 
markers, plasma antioxidant 
vitamin (retinol, tocopherol, 
carotenoids, coenzyme Q10),  
ex vivo H2O2-provoked 
oxidative DNA damage 
25
 
1 Some of the entries were derived from 28 324 
2 Quercetin aglycone, unless otherwise stated. 325 
3 Calculation is based on 16.6-fold since 166 mg quercetin aglycones from supplements would be comparable to 10 mg 326 
quercetin aglycone equivalents from onions according to this study. 327 
4
 Healthy subjects, unless otherwise stated.328 
16 
 
FIGURE LEGENDS  329 
Figure 1 HPLC chromatograms of A) quercetin standards B) supplement extracts and C) onion extracts 330 
at 255 nm (dash line) and 370 nm (solid line): (1) quercetin 3,4'-O-diglucoside; (2) quercetin 4'-O-331 
glucoside; (3) daidzein (i.s.); (4) quercetin.  332 
 333 
Figure 2 LC-MS chromatogram of quercetin and methylquercetLQDIWHUȕ±glucuronidase and sulfatase 334 
hydrolysis of urine.  335 
 336 
Figure 3 Urinary excretion of quercetin and methyl quercetin (mean ± SEM). 1800 ± 150 µmol 337 
quercetin from supplements or 156.3 ± 3.4 µmol quercetin from red onion soup was provided to each 338 
individual on separate occasions. 339 
  340 
17 
 
 341 
Figure 1  342 
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Figure 3 351 
